PhRMA and BIO say Biden’s march-in proposal creates uncertainty in industry

Nicole DeFeudis

Editor

PhRMA president Stephen Ubl argued Thursday that the Biden administration’s new proposal on the use of march-in rights has “planted the seeds of uncertainty” around …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PhRMA and BIO say Biden’s march-in proposal creates uncertainty in industry

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

PhRMA and BIO say Biden’s march-in pro­pos­al cre­ates un­cer­tain­ty in in­dus­try

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

PhRMA and BIO say Biden’s march-in proposal creates uncertainty in industry